

Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.
You can purchase shares of Fennec Pharmaceuticals (NASDAQ:FENC) through any online brokerage.
Other companies in Fennec Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Fennec Pharmaceuticals has a consensus price target of $16.40.
The stock price for Fennec Pharmaceuticals (NASDAQ: FENC) is $10.24 last updated October 30, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Fennec Pharmaceuticals.
Fennec Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Fennec Pharmaceuticals.
Fennec Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The...